BioAge Labs to Present at Jefferies London Healthcare Conference
Rhea-AI Summary
BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in the Jefferies London Healthcare Conference. CEO and co-founder Kristen Fortney, PhD, will deliver a presentation at the conference, scheduled for November 19-21, 2024. The presentation will be available on-demand, with a live webcast scheduled for November 19 at 1:00-1:25 PM GMT. Interested parties can access the presentation replay through BioAge's investor relations website for approximately 30 days post-conference.
Positive
- None.
Negative
- None.
RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that Kristen Fortney, PhD, CEO and co-founder, will present at the Jefferies London Healthcare Conference, which takes place November 19–21, 2024.
The on-demand presentation will be available from through the conference site. To access the live webcast of the presentation (1:00-1:25 PM GMT on November 19), please register here. An archived replay of the webcast will be available through the Investors section of the BioAge website https://ir.bioagelabs.com for approximately 30 days following the conference.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that was observed to promote metabolism and prevent muscle atrophy on bed rest in a Phase 1b clinical trial. In mid-2024, BioAge initiated a Phase 2 trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. BioAge’s preclinical programs, based on novel insights from the company’s discovery platform built on human longevity data, address key pathways in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Elena Liapounova, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
FAQ
When is BioAge Labs (BIOA) presenting at the Jefferies London Healthcare Conference 2024?
How long will BioAge Labs' (BIOA) Jefferies conference presentation be available for replay?
What is the focus area of BioAge Labs' (BIOA) therapeutic development?
Where can investors access BioAge Labs' (BIOA) Jefferies conference presentation replay?
